Novo Nordisk reported a 65% increase in Q1 2026 operating profit, driven by a provision reversal related to the US 340B Drug Pricing Program and strong sales of its new Wegovy pill for obesity. Adjusted sales excluding the provision reversal fell 4% due to lower prices but were supported by GLP-1 volume growth. The Wegovy pill, launched in January 2026, quickly reached over 2 million prescriptions, marking the strongest GLP-1 launch in the US. Novo Nordisk raised its 2026 outlook, expecting adjusted sales and operating profit growth between -4% and -12% at constant exchange rates, reflecting confidence in GLP-1 product demand and ongoing pipeline progress.
Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protect...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
Novo Nordisk has experienced an IT security incident involving unauthorized access to some internal systems. The company is investigating with cybersecurity experts and has temporarily taken certain systems offline to protect its environment. While c...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy pill (semaglutide tablets) as the first daily oral GLP-1 treatment for adults with obesity or overweight with weight-related conditions. Based on the OASIS 4 trial,...
